$85.2 Million is the total value of Ally Bridge Group (NY) LLC's 19 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 180.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Buy | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $10,436,985 | +123.9% | 183,105 | +100.3% | 12.25% | +116.9% | |
| ITCI | New | INTRA-CELLULAR THERAPIES INC | $9,115,750 | – | 175,000 | +100.0% | 10.70% | – |
| AXSM | New | AXSOME THERAPEUTICS INC | $7,729,834 | – | 110,600 | +100.0% | 9.07% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $6,915,862 | – | 181,805 | +100.0% | 8.12% | – |
| MRUS | Buy | MERUS NV | $5,220,235 | -0.5% | 221,384 | +11.1% | 6.13% | -3.6% |
| New | AMYLYX PHARMACEUTICALS INC | $4,992,954 | – | 272,690 | +100.0% | 5.86% | – | |
| GERN | Buy | GERON CORP | $4,709,875 | -30.9% | 2,221,639 | +4.6% | 5.53% | -33.0% |
| ARDX | New | ARDELYX INC | $3,595,932 | – | 881,356 | +100.0% | 4.22% | – |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $3,232,524 | – | 281,089 | +100.0% | 3.79% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $3,061,527 | – | 70,283 | +100.0% | 3.59% | – |
| Buy | JASPER THERAPEUTICS INC | $2,200,915 | -36.2% | 3,144,164 | +24.9% | 2.58% | -38.2% | |
| Buy | CONTEXT THERAPEUTICS INC | $1,096,186 | +4.9% | 725,951 | +11.1% | 1.29% | +1.7% | |
| New | PROMIS NEUROSCIENCES INC | $1,053,351 | – | 531,915 | +100.0% | 1.24% | – | |
| New | MEDAVAIL HOLDINGS INC | $707,382 | – | 117,897 | +100.0% | 0.83% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.